Page last updated: 2024-12-06

eramide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

eramide: combination of practolol & clofibrate for treatment of angina pectoris [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID62413
CHEMBL ID1889091
SCHEMBL ID321657
MeSH IDM0055428

Synonyms (86)

Synonym
MLS002153967
smr001233306
di-paralene
histantin
PRESTWICK_967
chlorcyclizine hydrochloride
1620-21-9
(1-[(4-chlorophenyl)phenyl-methyl]-4-methylpiperazine)
cas-1620-21-9
NCGC00016589-01
piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-methyl-, monohydrochloride
chlorcyclizine monohydrochloride
nsc 169496
chlorcyclizine chloride
einecs 238-335-1
1-(p-chlorobenzhydryl)-4-methylpiperazine monohydrochloride
1-(p-chloro-alpha-phenylbenzyl)-4-methylpiperazine monohydrochloride
piperazine, 1-(p-chloro-alpha-phenylbenzyl)-4-methyl-, monohydrochloride
chlorcyclizine hcl
component of fedrazil
diparalene hydrochloride
ah-289 hydrochloride
perazil
1-(p-chlorobenzhydryl)-4-methylpiperazine hydrochloride
eramide
di-paralene monohydrochloride
wln: t6m dntj dyr&r dg &gh
chlorcylizine
14362-31-3
wln: t6n dntj ayr&r dg& d &gh
chlorocyclizine hydrochloride
nsc-169496
chlorcyclizinium chloride
1-(p-chloro-.alpha.-phenylbenzyl)-4-methylpiperazine hydrochloride
nsc169496
FT-0664522
HMS1570M13
nsc-756678
pharmakon1600-01500175
nsc756678
dtxcid5025360
dtxsid7045360 ,
tox21_110511
unii-npb7a7874u
npb7a7874u ,
1-(p-chloro-alpha-phenylbenzyl)-4-methylpiperazine hydrochloride
piperazine, 1-(p-chloro-alpha-phenylbenzyl)-4-methyl-, hydrochloride
chlorcyclizine hydrochloride [usp]
nsc 756678
piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-methyl-, hydrochloride
CHEMBL1889091
ah-289
chlor cyclizine hydrochloride
chlorcyclizine hydrochloride [mi]
chlorcyclizine hydrochloride [vandf]
1-(p-chloro-.alpha.-phenylbenzyl)-4-methylpiperazine monohydrochloride
chlorcyclizine hydrochloride [who-dd]
chlorcyclizine hydrochloride [ep monograph]
chlorcyclizine hydrochloride [mart.]
CCG-212523
MSIJLVMSKDXAQN-UHFFFAOYSA-N
SCHEMBL321657
AKOS022181227
MLS006010796
1-((4-chlorophenyl)(phenyl)methyl)-4-methylpiperazine hydrochloride
FT-0697779
SR-05000001920-3
sr-05000001920
chlorcyclizine hydrochloride 1.0 mg/ml in methanol (as free base)
J-009887
1-[(4-chlorophenyl)(phenyl)methyl]-4-methylpiperazine hydrochloride
CS-0062684
chlorcyclizine (hydrochloride)
HY-112067A
F15109
1-((4-chlorophenyl)(phenyl)methyl)-4-methylpiperazine xhydrochloride
Q27284988
1-((4-chlorophenyl)phenylmethyl)-4-methylpiperazine hydrochloride
1620-21-9 (hcl)
1-[(4-chlorophenyl)-phenylmethyl]-4-methylpiperazine;hydrochloride
chlorcyclizine-d4hydrochloride
1-((4-chlorophenyl)(phenyl)methyl)-4-methylpiperazinexhydrochloride
ahist
boninekids
chlorcyclizine hydrochloride (ep monograph)
chlorcyclizine hydrochloride (mart.)

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency10.00000.01846.806014.1254AID624417
TDP1 proteinHomo sapiens (human)Potency18.10940.000811.382244.6684AID686978; AID686979
estrogen nuclear receptor alphaHomo sapiens (human)Potency2.56170.000229.305416,493.5996AID743075
IDH1Homo sapiens (human)Potency20.59620.005210.865235.4813AID686970
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency5.62340.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency10.52730.000323.4451159.6830AID743065; AID743067
gemininHomo sapiens (human)Potency35.48130.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (10.00)29.6817
2010's7 (70.00)24.3611
2020's2 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.85 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index163.17 (26.88)
Search Engine Supply Index4.00 (0.95)

This Compound (52.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]